Quest Diagnostics extends Alzheimer's disease portfolio with AI-enabled test service

Brain Puzzle Dementia Social

Quest Diagnostics on Thursday announced the nationwide availability of the RestoreU Dementia Panel, a risk assessment and care plan service created by uMethod Health

uMethod is a health technology company specializing in precision medicine for chronic diseases. The RestoreU service employs artificial intelligence (AI) that it developed to create personalized care plans aimed at helping physicians improve patient care while also satisfying cognitive care guidelines.

The service incorporates results of laboratory tests ordered by physicians from Quest Diagnostics along with the patient's health history, including comorbidities, lifestyle habits, and medications. uMethod’s AI platform then assesses 50-plus risk factors, pinpointing areas of concern and ultimately generating a personalized care plan with evidence-based, actionable treatment recommendations, Quest said.

With insights from the report, physicians may identify potentially reversible causes of cognitive decline, such as medication side effects or hormonal imbalances, that mimic dementia. The report may also help identify measures to potentially slow or, if possible, halt dementia disease progression, according to Quest.

Care plans may include pharmacological and supplementation-based treatment and lifestyle habit recommendations, which the physician can use to counsel the patient. The RestoreU service is an adjunct to, and not intended to replace, the physician's judgment.

Quest said the RestoreU service complements its portfolio of dementia laboratory services, featuring the AD-Detect Amyloid Beta (AB) 42/40 Ratio blood test for assessing risk of Alzheimer's disease. RestoreU can help the physician further refine this risk assessment, identify alternative possible causes of cognitive dysfunction and inform care, Quest said.

Page 1 of 4
Next Page